An outside of the united states (ous) customer contacted a siemens customer care center (ccc).Quality controls (qc) recovered in range at the time of the event.There is no indication of a system or assay issue.Siemens determined that heterophilic antibodies or elevated monoclonal immunoglobulin concentrations interferences potentially contributed to the falsely low free light chains, type lambda (flc lambda) result.As per the instructions for use for n latex flc lambda: "patient samples may contain heterophilic antibodies that could react in immunoassays to give a falsely elevated or depressed result.Excessively elevated monoclonal immunoglobulin concentrations might have the potential to suppress the reaction of anti-flc antibodies with free light chain molecules.If results do not fit to previous ones, or to results of other tests (e.G.Serum immunoelectrophoresis, immunofixation, differential blood cell count) and/or to the clinical situation, it is recommended to re-analyze the sample in a higher sample dilution." the system is performing according to specifications.No further evaluation of this device is required.
|
A falsely low free light chains, type lambda (flc lambda) result was obtained on a patient sample on a bn prospec system using n latex flc lambda reagent.The discordant result was not reported to the physician(s).The sample was then rerun using a 1:100 sample dilution for flc lambda using the same system and reagent, recovering higher.The higher result was reported, as the correct result, to the physician(s).The repeat result was confirmed using the electrophoresis analysis for this patient.There are no known reports of patient intervention or adverse health consequences due to the falsely low flc lambda result.
|